SCHEMBL15919450

SCHEMBL15919450

CC(C)(C)OC(=O)NNC(=O)c1cc(-c2ccc(-c3ccc(OCC(=O)N4CCOCC4)cc3)cc2)nc2ccncc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 6/20 0.45
HPGD P15428 5/20 0.45
FKBP1A P62942 4/20 0.45
USP2 O75604 2/20 0.45
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 3/20 0.43
GAA P10253 1/20 0.43
POLB P06746 3/20 0.42
ACACB O00763 1/20 0.42
ACACA Q13085 1/20 0.42
HTT P42858 1/20 0.41
MAPT P10636 4/20 0.41
NPC1 O15118 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 2/20 0.41
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15919659 0.89 KDM4E (0.44) L3MBTL1ALDH1A1HPGDUSP2KDM4E
SCHEMBL15919452 0.88 L3MBTL1 (0.49) L3MBTL1ALDH1A1HPGDFKBP1AUSP2
SCHEMBL15919743 0.87 L3MBTL1 (0.51) L3MBTL1ALDH1A1HPGDFKBP1AUSP2
Hydrochloric Acid SCHEMBL15905480 0.86 L3MBTL1 (0.51) L3MBTL1ALDH1A1HPGDFKBP1AUSP2
SCHEMBL15919445 0.84 MAPT (0.48) ALDH1A1HPGDUSP2KDM4EHSD17B10
SCHEMBL15919457 0.83 ALDH1A1 (0.45) ALDH1A1HPGDKDM4EHSD17B10POLB
SCHEMBL15905078 0.79 MEN1 (0.51) ALDH1A1KDM4EGAAACACBACACA
SCHEMBL15919688 0.78 MCL1 (0.45) ALDH1A1HPGDKDM4EGAAPOLB
SCHEMBL15919419 0.78 ACACB (0.44) KDM4EGAAACACBACACAHTT
SCHEMBL15919508 0.78 ACACB (0.48) ALDH1A1KDM4EGAAACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO L3MBTL1 1568/4885ALDH1A1 289/4885HPGD 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.